Metabolic, transcriptomic, and proteomic profiling of relapsed glioblastoma
Study of Metabolic, Genomic and Proteomic Modifications in Relapsed Glioblastoma. Identification or Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma.
University Hospital, Bordeaux · NCT06430424
This project will see if comparing genes, proteins, and metabolism in original versus relapsed tumors can reveal markers or targets for people with relapsed IDH‑wildtype glioblastoma who had repeat surgery at CHU de Bordeaux.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Bordeaux (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Bordeaux) |
| Trial ID | NCT06430424 on ClinicalTrials.gov |
What this trial studies
This retrospective observational project analyzes archived tumor specimens from adults with IDH‑wildtype glioblastoma who underwent both initial and repeat surgery at CHU de Bordeaux between 2005 and 2023. Paired primary and recurrent samples will undergo transcriptomic, proteomic, and metabolic profiling to identify molecular changes linked to relapse. Findings will be correlated with relapse‑free and overall survival to search for prognostic markers. No interventions are given; the work uses existing tissue and clinical records.
Who should consider this trial
Good fit: Adults over 18 who had both primary and recurrent glioblastoma surgery at CHU de Bordeaux between 2005 and 2023 and whose tumor tissue is available are eligible.
Not a fit: Patients who did not have both surgeries at CHU de Bordeaux, lack available paired tumor samples, have non‑IDH‑wildtype tumors, or received systemic therapy for a non‑glioblastoma cancer are unlikely to be included or to benefit from this retrospective analysis.
Why it matters
Potential benefit: If successful, the work could identify prognostic markers or new therapeutic targets that guide future treatments for relapsed glioblastoma.
How similar studies have performed: Prior multi‑omics studies in glioblastoma have identified candidate markers and pathways but have seldom led directly to new effective therapies, so this approach builds on existing work but remains exploratory.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age \> 18 years * surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux Exclusion Criteria: * systemic therapy received for non-glioblastoma tumor
Where this trial is running
Bordeaux
- CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médicale — Bordeaux, France (RECRUITING)
Study contacts
- Study coordinator: Mathieu LARROQUETTE
- Email: mathieu.larroquette@chu-bordeaux.fr
- Phone: +33 5 56 79 58 08
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Relapsed Cancer, Glioblastoma IDH Wildtype, Recurrent glioblastoma, Prognostic, Metabolism, Proteomic, Transcriptomic, Microbiota